Abstract
Devic disease, also known as neuromyelitis optica, is a severe rare condition characterized clinically by one or more episodes of optical neuritis and myelitis. Pathologically, it is characterized by extensive demyelination associated with axon loss and deposits of complement and immunoglobulins (IgM) within the lesions. Specific antibodies for this disease (IgG NMO) were recently identified. Immunosuppressive treatment is currently the best option for preventing relapse.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Azathioprine / administration & dosage
-
Azathioprine / therapeutic use
-
Child
-
Diagnosis, Differential
-
Drug Therapy, Combination
-
Female
-
Humans
-
Immunoglobulin G / analysis
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / therapeutic use
-
Interferon-beta / administration & dosage
-
Interferon-beta / therapeutic use
-
Magnetic Resonance Imaging
-
Male
-
Neuromyelitis Optica* / diagnosis
-
Neuromyelitis Optica* / drug therapy
-
Neuromyelitis Optica* / immunology
-
Neuromyelitis Optica* / therapy
-
Plasmapheresis
-
Prognosis
-
Retrospective Studies
-
Rituximab
-
Spinal Puncture
-
Time Factors
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Immunoglobulin G
-
Immunologic Factors
-
Immunosuppressive Agents
-
Rituximab
-
Interferon-beta
-
Azathioprine